Loading resource…

Copenhagen University Hospital Rigshospitalet
SGLT2 inhibitors have emerged as a critical treatment option for patients with heart failure and chronic kidney disease, supported by substantial clinical trial evidence. The document emphasizes the need for effective strategies to identify and treat patients who could benefit from these medications, particularly those without specialist care. It also addresses the importance of understanding the cost-effectiveness of SGLT2 inhibitors across different patient subgroups and the potential for improving public health outcomes through better implementation strategies.
No account needed